Welcome to Theranostic Trials by Telix Pharmaceuticals

About Telix

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals.

With nuclear medicine finally coming of age, Telix’s goal is to harness this momentum for the benefit of patients. We are investigating how molecularly targeted radiation (MTR) can support imaging approaches and personalised therapy.

Telix is headquartered in Melbourne, Australia with international operations in Belgium, Switzerland, Japan and the United States.

Telix’s core development pipeline is focused on prostate, kidney, brain (glioblastoma), and hematologic cancers.

Purpose of Theranostic Trials

Theranostic Trials is a non-promotional, educational resource for healthcare professionals.

Bringing together information about radiopharmaceutical diagnostic and therapeutic (‘theranostic’) approaches, Theranostic Trials aims to help facilitate transparent scientific exchange regarding developments in theranostic medical research and ongoing clinical trials (both company sponsored and in collaboration with leading global cancer centres), as well as providing background information on the surrounding disease areas.

Telix Research Pipeline

Shaded sections indicate expected development stage in the next 12 months.

  1. Prostate-specific membrane antigen.
  2. Carbonic anhydrase IX.
  3. Large amino acid transporter 1.
  4. Bone Marrow Conditioning / Rare Diseases.
  5. Cluster of differentiation 66.

* Registry Study


With the exception of Telix’s 68GA PSMA-11 imaging agent in Australia, Canada, and the United States, none of Telix’s products have received marketing authorisation in any jurisdiction.
Any use of Telix products is on an investigational basis only.